[HTML][HTML] Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in …
M Lauten, A Möricke, R Beier, M Zimmermann… - …, 2012 - ncbi.nlm.nih.gov
M Lauten, A Möricke, R Beier, M Zimmermann, M Stanulla, B Meissner, E Odenwald…
haematologica, 2012•ncbi.nlm.nih.govBackground In the ALL-BFM 95 trial for treatment of acute lymphoblastic leukemia, response
to a prednisone pre-phase (prednisone response) was used for risk stratification in
combination with age and white blood cell count at diagnosis, response to induction therapy
and specific genetic high-risk features.
to a prednisone pre-phase (prednisone response) was used for risk stratification in
combination with age and white blood cell count at diagnosis, response to induction therapy
and specific genetic high-risk features.
Abstract
Background
In the ALL-BFM 95 trial for treatment of acute lymphoblastic leukemia, response to a prednisone pre-phase (prednisone response) was used for risk stratification in combination with age and white blood cell count at diagnosis, response to induction therapy and specific genetic high-risk features.
ncbi.nlm.nih.gov